Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Outpatient Administration of Brexucabtagene Autoleucel (brexu-cel) for Acute Lymphoblastic Leukemia (ALL) and Mantle Cell Lymphoma (MCL) Is Safe and Feasible

Tamer Othman, John H. Baird, Yan Wang, Stacy Pak, Ibrahim Aldoss, Ji-Lian Cai, Alexey Danilov, Tycel J. Phillips, Vaibhav Agrawal, Karamjeet S Sandhu, Matthew Mei, Paul B. Koller, Joycelynne Michelle Palmer, Stephen J. Forman, Lihua E. Budde, Ahmed Aribi

Blood (2024) 144 (Supplement 1): 2278.

https://doi.org/10.1182/blood-2024-207085

Published: 2024

Journal Articles

Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administration in Combination with Reduced Intensity Conditioning

Haris Ali, MD, David Snyder, MD, Tracy Stiller, MS, Timothy Synold, PhD, Saloomeh Mokhtari, Joycelynne Palmer, PhD, Amandeep Salhotra, MD, Vinod A. Pullarkat, MD, Ji-lian Cai, MD, Stephen J Forman, MD, Matthew Mei, MD, Ryotaro Nakamura, MD

Blood (2019) 134 (Supplement_1): 669.

https://doi.org/10.1182/blood-2019-127445

Published: 2019

Journal Articles

Phase II Trial of Bortezomib Plus Rituximab As Maintenance Therapy Post ASCT for Patients with Mantle Cell Lymphoma

Robert W. Chen, MD, Joycelynne M. Palmer, PhD, Leslie Popplewell**, MD, Jessica Alluin, Pritsana Chomchan, Auayporn P. Nademanee, MDBS, Tanya Siddiqi, MD, Nicole Tsai, Fay Zuo, Rosie Abary, Ji-lian Cai, Steven T. Rosen, MD, Stephen J. Forman, MD FACP, Larry W Kwak, MDPhD, Leona Holmberg, MD PhD

Blood (2017) 130 (Supplement 1): 4515.

https://doi.org/10.1182/blood.V130.Suppl_1.4515.4515

Published: 2017

Journal Articles

Post Transplant Outcome of a Multicenter Phase II Study of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT

Robert Chen, Joycelynne Palmer, PhD, Peter Martin, MD, Saro Armenian, DO, MPH, Nichun Tsai, Michelle Mott, Firoozeh Sahebi, Ji-Lian Cai, MD PhD, Tanya Siddiqi, MD, Leslie L. Popplewell, MD, John P. Leonard, MD, Auayporn P. Nademanee, MD, Steven T. Rosen, MD, Larry W. Kwak, MD, Stephen J. Forman, MD

Blood (2015) 126 (23): 519.

https://doi.org/10.1182/blood.V126.23.519.519

Published: 2015

Journal Articles

Randomized Trial of a Novel CMV Vaccine (CMVPepVax) after Allogeneic HCT: Elevated CMV-Specific Immune Response, Reduction in Chronic GvHD and CMV Reactivation Only in Vaccine Arm Patients

Ryotaro Nakamura, MD, Corinna La Rosa, PhD, Jeff Longmate, PhD, Margaret O'Donnell, MD FRCPC, Ji-Lian Cai, MD, Len Farol, MD, Amandeep Salhotra, MD, David S Snyder, MD, Jennifer Drake, Cynthia Slape, James Merson, PhD, John A Zaia, MD, Stephen J. Forman, Don J. Diamond, PhD

Blood (2014) 124 (21): 183.

https://doi.org/10.1182/blood.V124.21.183.183

Published: 2014

Journal Articles

Brentuximab Vedotin Improves HCT-CI, CR Status, and Peri-Transplant Toxicity In Patients With Relapsed/Refractory Hodgkin Lymphoma Heading To RIC Allo-HCT

Robert Chen, MD, Joycelynne Palmer, PhD, Ni-Chun Tsai, MS MPH, Sandra H. Thomas, PhD, Tanya Paris, Leslie Popplewell, MD, Chatchada Karanes, MD, Tanya Siddiqi, MD, Auayporn Nademanee, MD, Ji-Lian Cai, MD, Stephen J. Forman, MD

Blood (2013) 122 (21): 3374.

https://doi.org/10.1182/blood.V122.21.3374.3374

Published: 2013

Journal Articles

Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL

Robert W. Chen, MD, Joycelynne Palmer, PhD, Tanya Siddiqi, MD, Sandra H. Thomas, PhD, Young Kim, MD, Chen T Binhong, MD, Amrita Krishnan, MD, Nitya Nathwani, MD, Ji-Lian Cai, MD, PhD, Michelle Mott, RN, Deron Matsuoka, BS, Stephen J Forman, MD

Blood (2012) 120 (21): 3699.

https://doi.org/10.1182/blood.V120.21.3699.3699

Published: 2012

Journal Articles

High Rate of Complete Remission (CR) and Upgraded Response with Weekly Maintenance Bortezomib Post Single Autologous Peripheral Stem Cell Transplant (PSCT) In Patients with Multiple Myeloma. Results of a Phase II Prospective Study

Firoozeh Sahebi, M.D., Amrita Krishnan, M.D., Leonardo Farol, MD, Ji-Lian Cai, MD, George Somlo, MD, Leslie Popplewell, M.D., R. Spielberger, M.D., Neil Martin Kogut, MD, Chatchada Karanes, MD, Christopher Ruel, Paul Frankel, Eunicia Reburiano, Margret O'Donnell, MD, Stephen Forman

Blood (2010) 116 (21): 2399.

https://doi.org/10.1182/blood.V116.21.2399.2399

Published: 2010

Journal Articles

Improved Outcome After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation (RI-HCT) for Myelodysplastic Syndrome (MDS) Using Tacrolimus/Sirolimus-Based Gvhd Prophylaxis.

Ryotaro Nakamura, MD, Joycelynne Palmer, Pablo Parker, Anthony Stein, Tracey Stiller, Vinod Pullarkat, David S. Snyder, MD, Ji-Lian Cai, MD, PhD, Shirong Wang, MD, MPH, David Senitzer, PhD, Karen L. Chang, Ravi Bhatia, Stephen J Forman, MD, Margaret O'Donnell, MD

Blood (2009) 114 (22): 2771.

https://doi.org/10.1182/blood.V114.22.2771.2771

Published: 2009

Journal Articles

A Phase II Study of Sequential Velcade/Thalidomide/ Dexamethasone (VTD) as Maintenance Therapy Post Single Autologous Peripheral Stem Cell (PSCT) in Patients with Multiple Myeloma.

Firoozeh Sahebi, Amrita Krishnan, MD, FACP, George Somlo, MD, Leslie Popplewell, P. Parker, Ji-Lian Cai, MD, PhD, Len Farol, MD, Ricardo Spielberger, Neil Martin Kogut, MD, Chatchada Karanes, Christopher Ruel, Paul Frankel, Fermin Arceo, Lupe Duarte, CRRC, Margaret O'Donnell, MD, Stephen J Forman, MD

Blood (2009) 114 (22): 3403.

https://doi.org/10.1182/blood.V114.22.3403.3403

Published: 2009

Journal Articles

Analysis of Predictive Power of Prednisone Dose at 3 Months of Treatment on CGVHD Prognosis.

Blood (2007) 110 (11): 1975.

https://doi.org/10.1182/blood.V110.11.1975.1975

Published: 2007

Journal Articles

Similar Outcome with Early Reduced Intensity Conditioning (RIC) Allogeneic Transplant to Autologous-Non-Myeloablative Allogeneic (Auto-Allo) Transplant in Patients with Multiple Myeloma.

Sahebi Firoozeh, MD, Jeffery R. Schriber, M.D., Ricardo Spielberger, M.D., Ji-Lian Cai, M.D., Neil Martin Kogut, M.D., Peter M. Falk, M.D., Pablo Miguel Parker, M.D., Amrita Krishnan, M.D., Leslie Popplewell, M.D., Chatchada Karanes, M.D., Dajun Qian, PhD., Stephen J. Forman, M.D., George Somlo, M.D.

Blood (2007) 110 (11): 3030.

https://doi.org/10.1182/blood.V110.11.3030.3030

Published: 2007

NARROW

Outpatient Administration of Brexucabtagene Autoleucel (brexu-cel) for Acute Lymphoblastic Leukemia (ALL) and Mantle Cell Lymphoma (MCL) Is Safe and Feasible

Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administration in Combination with Reduced Intensity Conditioning

Phase II Trial of Bortezomib Plus Rituximab As Maintenance Therapy Post ASCT for Patients with Mantle Cell Lymphoma

Post Transplant Outcome of a Multicenter Phase II Study of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT

Randomized Trial of a Novel CMV Vaccine (CMVPepVax) after Allogeneic HCT: Elevated CMV-Specific Immune Response, Reduction in Chronic GvHD and CMV Reactivation Only in Vaccine Arm Patients

Brentuximab Vedotin Improves HCT-CI, CR Status, and Peri-Transplant Toxicity In Patients With Relapsed/Refractory Hodgkin Lymphoma Heading To RIC Allo-HCT

Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL

High Rate of Complete Remission (CR) and Upgraded Response with Weekly Maintenance Bortezomib Post Single Autologous Peripheral Stem Cell Transplant (PSCT) In Patients with Multiple Myeloma. Results of a Phase II Prospective Study

Improved Outcome After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation (RI-HCT) for Myelodysplastic Syndrome (MDS) Using Tacrolimus/Sirolimus-Based Gvhd Prophylaxis.

A Phase II Study of Sequential Velcade/Thalidomide/ Dexamethasone (VTD) as Maintenance Therapy Post Single Autologous Peripheral Stem Cell (PSCT) in Patients with Multiple Myeloma.

Analysis of Predictive Power of Prednisone Dose at 3 Months of Treatment on CGVHD Prognosis.

Similar Outcome with Early Reduced Intensity Conditioning (RIC) Allogeneic Transplant to Autologous-Non-Myeloablative Allogeneic (Auto-Allo) Transplant in Patients with Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only